Can You Take Flexeril with a Pacemaker?
Yes, cyclobenzaprine (Flexeril) can generally be taken safely by patients with cardiac pacemakers, as there is no absolute contraindication for pacemaker patients specifically. However, the FDA label explicitly contraindicates cyclobenzaprine in patients with arrhythmias, heart block, or conduction disturbances 1, which means the underlying cardiac condition that necessitated the pacemaker—not the pacemaker itself—determines safety.
Key Contraindications from FDA Labeling
The FDA drug label for cyclobenzaprine clearly states contraindications that are relevant to cardiac patients 1:
- Arrhythmias
- Heart block or conduction disturbances
- Congestive heart failure
- Acute recovery phase of myocardial infarction
Clinical Decision Algorithm
If the pacemaker was placed for:
Complete heart block or high-grade AV block: Cyclobenzaprine is contraindicated based on the underlying conduction disease 1. The pacemaker does not eliminate this contraindication—it only manages the bradycardia consequence.
Sick sinus syndrome or sinus node dysfunction: Exercise caution. While the pacemaker provides rate support, cyclobenzaprine's anticholinergic effects and potential for cardiac conduction effects make this a relative contraindication 2.
Prophylactic indication (e.g., post-cardiac surgery, bifascicular block): May be safer, but still requires careful consideration of the underlying cardiac substrate.
Cardiac resynchronization therapy (CRT) for heart failure: Absolutely contraindicated due to the explicit FDA contraindication in congestive heart failure 1.
Important Caveats and Drug Interactions
Cyclobenzaprine is structurally related to tricyclic antidepressants and possesses anticholinergic properties 2. While overdose studies show it is less cardiotoxic than traditional tricyclics 3, case reports demonstrate it can cause:
- Sodium channel blockade leading to QRS prolongation 4
- Cardiac arrest when combined with other sodium channel blockers 4
- Bradycardia and conduction delays through anticholinergic mechanisms 2
The perioperative guideline recommends holding cyclobenzaprine on the day of operation due to potential interactions with anesthetic agents and anticholinergic effects 2, suggesting meaningful cardiac effects exist even at therapeutic doses.
Practical Management
If cyclobenzaprine must be used in a pacemaker patient:
- Verify the pacemaker indication does not involve active arrhythmias, heart block, or heart failure
- Ensure the pacemaker is functioning properly and recently interrogated
- Avoid combining with other medications that affect cardiac conduction (Class IC antiarrhythmics, other anticholinergics, QT-prolonging drugs) 5, 4
- Monitor for symptoms of hypotension, dizziness, or worsening cardiac function 2
- Use the lowest effective dose for the shortest duration (2-3 weeks maximum) 1
Safer alternatives for muscle spasm in pacemaker patients include: methocarbamol, which has a better cardiac safety profile 2, or non-pharmacologic approaches.
The critical point is that the pacemaker itself does not make cyclobenzaprine safe—the underlying cardiac pathology that required pacing determines risk, and many pacemaker indications overlap with cyclobenzaprine's cardiac contraindications.